Rocket Pharma Wins FDA Approval For KRESLADI — The First Ever Gene Therapy For Severe LAD-I

The FDA granted accelerated approval to KRESLADI, Rocket Pharmaceuticals' one-time gene therapy for severe Leukocyte Adhesion Deficiency-I. This is a transformative regulatory milestone that enables commercialization and should be highly value-accretive to Rocket (RCKT), likely driving a material positive stock reaction and near-term commercial and reimbursement planning.

Analysis

The FDA granted accelerated approval to KRESLADI, Rocket Pharmaceuticals' one-time gene therapy for severe Leukocyte Adhesion Deficiency-I. This is a transformative regulatory milestone that enables commercialization and should be highly value-accretive to Rocket (RCKT), likely driving a material positive stock reaction and near-term commercial and reimbursement planning.